BRPI0809926B8 - composição que compreende antígenos de mycobacterium tuberculosis, polipeptídeo de fusão isolado, polinucleotídeo isolado que codifica o dito polipeptídeo e uso da dita composição para estimular uma resposta imune protetora - Google Patents

composição que compreende antígenos de mycobacterium tuberculosis, polipeptídeo de fusão isolado, polinucleotídeo isolado que codifica o dito polipeptídeo e uso da dita composição para estimular uma resposta imune protetora

Info

Publication number
BRPI0809926B8
BRPI0809926B8 BRPI0809926A BRPI0809926A BRPI0809926B8 BR PI0809926 B8 BRPI0809926 B8 BR PI0809926B8 BR PI0809926 A BRPI0809926 A BR PI0809926A BR PI0809926 A BRPI0809926 A BR PI0809926A BR PI0809926 B8 BRPI0809926 B8 BR PI0809926B8
Authority
BR
Brazil
Prior art keywords
composition
polypeptide
antigens
isolated
stimulate
Prior art date
Application number
BRPI0809926A
Other languages
English (en)
Inventor
C Ireton Gregory
N Coler Rhea
G Reed Steven
Original Assignee
Infectious Disease Res Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Infectious Disease Res Inst filed Critical Infectious Disease Res Inst
Publication of BRPI0809926A2 publication Critical patent/BRPI0809926A2/pt
Publication of BRPI0809926B1 publication Critical patent/BRPI0809926B1/pt
Publication of BRPI0809926B8 publication Critical patent/BRPI0809926B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/35—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Mycobacteriaceae (F)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/285—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Pasteurellaceae (F), e.g. Haemophilus influenza
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56911—Bacteria
    • G01N33/5695—Mycobacteria
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2469/00—Immunoassays for the detection of microorganisms
    • G01N2469/20—Detection of antibodies in sample from host which are directed against antigens from microorganisms
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Communicable Diseases (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Pulmonology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)

Abstract

composições imunogênicas compreendendo polipeptídios de mycobacterium tuberculosis e fusões dos mesmos. a presente invenção se refere a composições e proteínas de fusão contendo pelo menos dois antígenos de mycobacterium sp., polinucleotídios codificando tais composições e proteínas de fusão. a invenção também se refere a métodos para seus usos no tratamento, prevenção e/ou diagnóstico de infecção por tuberculose.
BRPI0809926A 2007-04-04 2008-04-04 composição que compreende antígenos de mycobacterium tuberculosis, polipeptídeo de fusão isolado, polinucleotídeo isolado que codifica o dito polipeptídeo e uso da dita composição para estimular uma resposta imune protetora BRPI0809926B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US91016907P 2007-04-04 2007-04-04
US60/910.169 2007-04-04
PCT/US2008/059500 WO2008124647A2 (en) 2007-04-04 2008-04-04 Immunogenic compositions comprising mycobacterium tuberculosis polypeptides and fusions thereof

Publications (3)

Publication Number Publication Date
BRPI0809926A2 BRPI0809926A2 (pt) 2014-10-07
BRPI0809926B1 BRPI0809926B1 (pt) 2020-09-29
BRPI0809926B8 true BRPI0809926B8 (pt) 2021-05-25

Family

ID=39620241

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0809926A BRPI0809926B8 (pt) 2007-04-04 2008-04-04 composição que compreende antígenos de mycobacterium tuberculosis, polipeptídeo de fusão isolado, polinucleotídeo isolado que codifica o dito polipeptídeo e uso da dita composição para estimular uma resposta imune protetora

Country Status (11)

Country Link
US (6) US8486414B2 (pt)
EP (2) EP3199176B1 (pt)
JP (3) JP5378350B2 (pt)
CN (2) CN104815324A (pt)
BR (1) BRPI0809926B8 (pt)
DK (1) DK2136836T3 (pt)
ES (1) ES2621211T3 (pt)
MX (2) MX351247B (pt)
PL (1) PL2136836T3 (pt)
WO (1) WO2008124647A2 (pt)
ZA (1) ZA200907316B (pt)

Families Citing this family (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2428801B1 (en) * 2006-03-14 2014-05-07 Oregon Health and Science University Methods for detecting a mycobacterium tuberculosis infection
BRPI0809926B8 (pt) 2007-04-04 2021-05-25 Infectious Disease Res Inst composição que compreende antígenos de mycobacterium tuberculosis, polipeptídeo de fusão isolado, polinucleotídeo isolado que codifica o dito polipeptídeo e uso da dita composição para estimular uma resposta imune protetora
EP3263124A1 (en) * 2009-11-20 2018-01-03 Oregon Health & Science University Methods for producing an immune response to tuberculosis
WO2012057904A1 (en) * 2010-10-27 2012-05-03 Infectious Disease Research Institute Mycobacterium tuberculosis antigens and combinations thereof having high seroreactivity
EP2573107A1 (en) * 2011-09-21 2013-03-27 Norwegian Institute of Public Health A recombinant fusion protein
WO2013090897A1 (en) * 2011-12-15 2013-06-20 The Trustees Of The University Of Pennsylvania Using adaptive immunity to detect drug resistance
CN102586139B (zh) * 2012-01-20 2013-03-20 广东本科生物工程股份有限公司 一种高产ad/add的菌株及高效生产ad/add的方法
EP2811981B1 (en) 2012-02-07 2019-05-08 Infectious Disease Research Institute Improved adjuvant formulations comprising tlr4 agonists and methods of using the same
US9404923B2 (en) * 2012-02-07 2016-08-02 Intuitive Biosciences, Inc. Mycobacterium tuberculosis specific peptides for detection of infection or immunization in non-human primates
US10048561B2 (en) 2013-02-21 2018-08-14 View, Inc. Control method for tintable windows
EA029492B1 (ru) 2012-07-10 2018-04-30 Трансген Са Вакцина на основе микобактериальных антигенов
EP4299138A3 (en) * 2012-08-03 2024-08-14 Access to Advanced Health Institute Compositions and methods for treating an active mycobacterium tuberculosis infection
CN102899334B (zh) * 2012-10-29 2015-02-25 英诺特（唐山）生物技术有限公司 一种结核分枝杆菌重组蛋白质及其制备方法
EP2968496A4 (en) 2013-03-15 2016-07-27 Univ Pennsylvania SYNTHETIC IMMUNOGENES FOR PROPHYLAXIS OR TREATMENT OF TUBERCULOSIS
CN104237509B (zh) * 2013-06-19 2015-12-02 华中农业大学 一种结核分枝杆菌的检测试剂盒及应用
CN104237508B (zh) * 2013-06-19 2015-12-02 华中农业大学 一种结核分枝杆菌的检测试剂盒及应用
EP4176897A1 (en) 2013-06-25 2023-05-10 International AIDS Vaccine Initiative, Inc. Tuberculosis compositions and methods of using the same
US10226522B2 (en) * 2013-08-30 2019-03-12 Globeimmune, Inc. Compositions and methods for the treatment or prevention of tuberculosis
US9504743B2 (en) 2013-09-25 2016-11-29 Sequoia Sciences, Inc Compositions of vaccines and adjuvants and methods for the treatment of urinary tract infections
US20150086592A1 (en) 2013-09-25 2015-03-26 Sequoia Sciences, Inc Compositions of vaccines and adjuvants and methods for the treatment of urinary tract infections
US9149521B2 (en) 2013-09-25 2015-10-06 Sequoia Sciences, Inc. Compositions of vaccines and adjuvants and methods for the treatment of urinary tract infections
US9149522B2 (en) 2013-09-25 2015-10-06 Sequoia Sciences, Inc. Compositions of vaccines and adjuvants and methods for the treatment of urinary tract infections
JP6249712B2 (ja) * 2013-10-09 2017-12-20 公益財団法人ヒューマンサイエンス振興財団 非傍腫瘍性急性脳炎患者の予後診断装置の作動方法
CN103698531B (zh) * 2013-11-25 2015-10-14 广东体必康生物科技有限公司 Rv1860、Rv0173和/或Rv1812c蛋白在制备诊断活动性肺结核的产品中的用途
IL310015B1 (en) 2013-12-31 2025-10-01 Access To Advanced Health Inst Single vial formulation
WO2015104380A1 (en) 2014-01-09 2015-07-16 Transgene Sa Fusion of heterooligomeric mycobacterial antigens
KR101477795B1 (ko) * 2014-04-23 2015-01-02 건국대학교 산학협력단 Ａｄｋ 단백질을 유효성분으로 포함하는 패혈증 또는 패혈증성 쇼크의 예방 또는 치료용 조성물
US10543258B2 (en) * 2014-12-10 2020-01-28 Konkuk University Glocal Industry-Academic Collaboration Foundation Antibacterial composition containing ADK protein as active ingredient, or composition for preventing or treating sepsis
KR101995622B1 (ko) * 2015-04-03 2019-07-02 건국대학교 글로컬산학협력단 Adk 단백질을 유효성분으로 포함하는 카바페넴 내성 그람음성균에 대한 항균용 조성물
CN106645733A (zh) * 2015-07-16 2017-05-10 广东体必康生物科技有限公司 用于特异性检测结核分枝杆菌感染的蛋白
IL299285B2 (en) 2016-05-16 2024-12-01 Access To Advanced Health Inst Formulation containing tlr agonist and methods of use
CA3023672A1 (en) 2016-05-16 2017-11-23 Infectious Disease Research Institute Pegylated liposomes and methods of use
EP3458088A2 (en) * 2016-05-21 2019-03-27 Infectious Disease Research Institute Compositions and methods for treating secondary tuberculosis and nontuberculous mycobacterium infections
CA3023271A1 (en) 2016-06-01 2017-12-07 Infectious Disease Research Institute Nanoalum particles containing a sizing agent
CA3027995A1 (en) 2016-06-16 2017-12-21 Aeras Tuberculosis compositions and methods of treating or preventing tuberculosis
CN109843321A (zh) 2016-06-22 2019-06-04 国际艾滋病疫苗行动组织公司 作为结核病疫苗的重组巨细胞病毒载体
EP3555630B1 (en) 2016-12-14 2023-05-31 Becton, Dickinson and Company Methods and compositions for obtaining a tuberculosis assessment in a subject
IL271384B2 (en) 2017-06-15 2025-02-01 Access To Advanced Health Inst Nanostructured lipid carriers and stable emulsions and their uses
CN107817228B (zh) * 2017-06-30 2022-06-14 四川农业大学 对E.coli O157:H7免酶及免荧光标记的检测方法
CN111315406A (zh) 2017-09-08 2020-06-19 传染病研究所 包括皂苷的脂质体调配物及其使用方法
US11638749B2 (en) 2017-10-17 2023-05-02 International Aids Vaccine Initiative, Inc. Tuberculosis antigen cassettes
US12195810B2 (en) 2017-12-22 2025-01-14 Massachusetts Eye And Ear Infirmary Comprehensive microbial panel for molecular diagnosis of eye infections
CA3098015A1 (en) 2018-04-26 2019-10-31 Children's National Medical Center Mycobacterial antigen compositions and methods of use
CN108411030B (zh) * 2018-05-25 2021-05-14 兰州大学 引物对及包含其的试剂盒、用途和检测蒺藜苜蓿生态型a17和r108的方法
CN108948175B (zh) * 2018-07-23 2020-11-20 首都医科大学附属北京胸科医院 与人类蛋白smad2相互作用的结核蛋白及其应用
WO2020059895A1 (ko) * 2018-09-17 2020-03-26 주식회사 큐라티스 스팅 작용자를 포함하는 면역항원보강제 및 백신 조성물
KR102524577B1 (ko) * 2019-04-22 2023-04-21 전남대학교산학협력단 플라젤린 융합 단백질 및 이의 용도
EP3964520A4 (en) * 2019-05-02 2023-05-10 L-Base Co.,Ltd. NEW OLIGOPEPTIDE AND PHARMACEUTICAL COMPOSITION FOR THE PREVENTION OR TREATMENT OF CANCER USING IT AS AN ACTIVE SUBSTANCE
WO2020243115A1 (en) 2019-05-25 2020-12-03 Infectious Disease Research Institute Composition and method for spray drying an adjuvant vaccine emulsion
EP3983011A1 (en) * 2019-06-14 2022-04-20 Statens Serum Institut Fusion proteins for tuberculosis vaccines
GB201909953D0 (en) * 2019-07-11 2019-08-28 Sec Dep For Environment Food And Rural Affairs Acting Through The Animal And Plant Health Agency Diagnostic reagents
US11679163B2 (en) 2019-09-20 2023-06-20 Hdt Bio Corp. Compositions and methods for delivery of RNA
CN111286551A (zh) * 2020-01-04 2020-06-16 昆明理工大学 结核分枝杆菌的快速检测引物、试剂盒及其使用方法
KR20220156933A (ko) 2020-03-23 2022-11-28 에이치디티 바이오 코포레이션 Rna의 전달을 위한 조성물 및 방법
EP4048308A1 (en) 2020-12-23 2022-08-31 Infectious Disease Research Institute Solanesol vaccine adjuvants and methods of preparing same
CN113121703B (zh) * 2021-03-03 2023-04-25 上海晶诺生物科技有限公司 一种具有结核杆菌免疫原性的融合蛋白及其应用
AU2022348995A1 (en) 2021-09-22 2024-04-11 Hdt Bio Corp. Cancer therapy compositions and uses thereof
JP2024535352A (ja) 2021-09-22 2024-09-30 エイチディーティー バイオ コーポレーション Ｓａｒｓ－ｃｏｖ－２ ｒｎａワクチン組成物および使用方法
CA3232658A1 (en) 2021-09-22 2023-03-30 Steven Gregory REED Rna vaccines against infectious diseases
JP2024535351A (ja) 2021-09-22 2024-09-30 エイチディーティー バイオ コーポレーション 乾燥ナノ粒子組成物
CN114150006B (zh) * 2021-11-29 2023-07-25 中国农业科学院植物保护研究所 一种可提高米尔贝霉素产量的基因簇、重组菌及其制备方法与应用
CN116284283A (zh) * 2021-12-13 2023-06-23 江苏瑞科生物技术股份有限公司 重组结核分枝杆菌抗原、其制备方法和应用
AU2023336224A1 (en) 2022-09-09 2025-03-27 Access To Advanced Health Institute Immunogenic vaccine composition incorporating a saponin
CN116041454B (zh) * 2022-12-07 2023-12-26 中国疾病预防控制中心传染病预防控制所 结核分枝杆菌蛋白抗原混合物、多抗原融合蛋白及编码基因、应用
NL2036756B1 (en) * 2024-01-05 2024-08-29 Univ Shihezi Fluorescent pcr method for detecting listeria monocytogenes and mycobacterium tuberculosis in milk
CN118987197B (zh) * 2024-10-24 2025-01-24 山东第二医科大学 一种自佐剂型热稳定纳米多价结核疫苗及其制备方法与应用

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235877A (en) 1979-06-27 1980-11-25 Merck & Co., Inc. Liposome particle containing viral or bacterial antigenic subunit
US4554101A (en) 1981-01-09 1985-11-19 New York Blood Center, Inc. Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity
US4866034A (en) 1982-05-26 1989-09-12 Ribi Immunochem Research Inc. Refined detoxified endotoxin
US4436727A (en) 1982-05-26 1984-03-13 Ribi Immunochem Research, Inc. Refined detoxified endotoxin product
US4751180A (en) 1985-03-28 1988-06-14 Chiron Corporation Expression using fused genes providing for protein product
US4935233A (en) 1985-12-02 1990-06-19 G. D. Searle And Company Covalently linked polypeptide cell modulators
US4877611A (en) 1986-04-15 1989-10-31 Ribi Immunochem Research Inc. Vaccine containing tumor antigens and adjuvants
US4761180A (en) 1986-08-27 1988-08-02 Hewlett-Packard Company Dyes containing tetramethylammonium cation for ink-jet printing inks
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
US5725871A (en) 1989-08-18 1998-03-10 Danbiosyst Uk Limited Drug delivery compositions comprising lysophosphoglycerolipid
US5707644A (en) 1989-11-04 1998-01-13 Danbiosyst Uk Limited Small particle compositions for intranasal drug delivery
US5466468A (en) 1990-04-03 1995-11-14 Ciba-Geigy Corporation Parenterally administrable liposome formulation comprising synthetic lipids
SE466259B (sv) 1990-05-31 1992-01-20 Arne Forsgren Protein d - ett igd-bindande protein fraan haemophilus influenzae, samt anvaendning av detta foer analys, vacciner och uppreningsaendamaal
US5399363A (en) 1991-01-25 1995-03-21 Eastman Kodak Company Surface modified anticancer nanoparticles
US5756353A (en) 1991-12-17 1998-05-26 The Regents Of The University Of California Expression of cloned genes in the lung by aerosol-and liposome-based delivery
ATE155681T1 (de) 1992-05-18 1997-08-15 Minnesota Mining & Mfg Einrichtung zur transmucosalen wirkstoffabgabe
UA40597C2 (uk) 1992-06-25 2001-08-15 Смітклайн Бічем Байолоджікалс С.А. Вакцинна композиція,спосіб лікування ссавців, що страждають або сприйнятливі до інфекції, спосіб лікування ссавців, що страждають на рак, спосіб одержання вакцинної композиції, композиція ад'ювантів
US5359681A (en) 1993-01-11 1994-10-25 University Of Washington Fiber optic sensor and methods and apparatus relating thereto
US5543158A (en) 1993-07-23 1996-08-06 Massachusetts Institute Of Technology Biodegradable injectable nanoparticles
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
DE69535036T3 (de) 1994-07-15 2011-07-07 The University of Iowa Research Foundation, IA Immunomodulatorische oligonukleotide
IE80468B1 (en) 1995-04-04 1998-07-29 Elan Corp Plc Controlled release biodegradable nanoparticles containing insulin
UA56132C2 (uk) 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
US6592877B1 (en) 1995-09-01 2003-07-15 Corixa Corporation Compounds and methods for immunotherapy and diagnosis of tuberculosis
US5856462A (en) 1996-09-10 1999-01-05 Hybridon Incorporated Oligonucleotides having modified CpG dinucleosides
US6113918A (en) 1997-05-08 2000-09-05 Ribi Immunochem Research, Inc. Aminoalkyl glucosamine phosphate compounds and their use as adjuvants and immunoeffectors
US6355257B1 (en) 1997-05-08 2002-03-12 Corixa Corporation Aminoalkyl glucosamine phosphate compounds and their use as adjuvants and immunoeffectors
EP1484405A1 (en) * 1997-11-10 2004-12-08 Statens Serum Institut Nucleic acid fragments and polypeptide fragments derived from M. Tuberculosis
GB9727262D0 (en) 1997-12-24 1998-02-25 Smithkline Beecham Biolog Vaccine
US20020081579A1 (en) 1998-02-13 2002-06-27 Jane E. R. Potter Method for the isolation of novel antigens
IL138809A0 (en) * 1998-04-07 2001-10-31 Corixa Corp Fusion proteins of mycobacterium tuberculosis antigens and pharmaceutical compositions containing the same
AU746163B2 (en) 1998-04-09 2002-04-18 Smithkline Beecham Biologicals (Sa) Adjuvant compositions
ES2257068T3 (es) 1998-08-10 2006-07-16 Antigenics Inc. Mezclas de adyuvantes de cpg y saponinas y metodos de empleo de las mismas.
JP2003510370A (ja) * 1999-10-07 2003-03-18 コリクサ コーポレイション Ｍｙｃｏｂａｃｔｅｒｉｕｍｔｕｂｅｒｃｕｌｏｓｉｓの融合タンパク質
US7472098B2 (en) 2000-02-14 2008-12-30 Ubs Financial Services, Inc. System and method for execution of trades made pursuant to stock option and purchase plans
WO2001098460A2 (en) 2000-06-20 2001-12-27 Corixa Corporation Fusion proteins of mycobacterium tuberculosis
AU2003224313A1 (en) 2002-04-27 2003-11-17 The Secretary Of State For Environment, Food And Rural Affairs Mycobacterial antigens and uses thereof
EP1523331B1 (en) 2002-07-13 2013-02-27 Statens Serum Institut Therapeutic tb vaccine
EP1786460A4 (en) * 2004-08-26 2008-04-02 Sequella Inc TEST FOR DETECTION OF TUBERCULOSIS IN NON-MENTAL PRIMATES
WO2006026464A2 (en) * 2004-08-27 2006-03-09 Davidsen Kevin P Handclapping aid
KR101035053B1 (ko) * 2005-06-23 2011-05-19 스태튼스 세룸 인스티튜트 감염 잠복기 동안 발현되는 항원을 포함하는 결핵 백신
LT2484375T (lt) 2006-09-26 2018-07-10 Infectious Disease Research Institute Vakcinos kompozicija, turinti sintetinio adjuvanto
BRPI0809926B8 (pt) 2007-04-04 2021-05-25 Infectious Disease Res Inst composição que compreende antígenos de mycobacterium tuberculosis, polipeptídeo de fusão isolado, polinucleotídeo isolado que codifica o dito polipeptídeo e uso da dita composição para estimular uma resposta imune protetora

Also Published As

Publication number Publication date
EP2136836B8 (en) 2017-04-12
ES2621211T3 (es) 2017-07-03
JP2014058520A (ja) 2014-04-03
JP2010524854A (ja) 2010-07-22
PL2136836T3 (pl) 2017-07-31
CN101687027A (zh) 2010-03-31
US8486414B2 (en) 2013-07-16
JP5922074B2 (ja) 2016-05-24
MX2009010800A (es) 2010-01-29
US20130209500A1 (en) 2013-08-15
EP3199176B1 (en) 2020-02-19
WO2008124647A3 (en) 2009-04-02
EP3199176A1 (en) 2017-08-02
WO2008124647A2 (en) 2008-10-16
US9822152B2 (en) 2017-11-21
US20240140997A1 (en) 2024-05-02
EP2136836A2 (en) 2009-12-30
MX351247B (es) 2017-10-05
US11091521B2 (en) 2021-08-17
JP5378350B2 (ja) 2013-12-25
BRPI0809926B1 (pt) 2020-09-29
CN101687027B (zh) 2015-01-28
US20100129391A1 (en) 2010-05-27
CN104815324A (zh) 2015-08-05
DK2136836T3 (en) 2017-04-10
US20220017578A1 (en) 2022-01-20
US20250304629A1 (en) 2025-10-02
US20180170975A1 (en) 2018-06-21
US11897922B2 (en) 2024-02-13
JP2016145209A (ja) 2016-08-12
ZA200907316B (en) 2013-03-27
US12344641B2 (en) 2025-07-01
BRPI0809926A2 (pt) 2014-10-07
EP2136836B1 (en) 2017-01-04

Similar Documents

Publication Publication Date Title
BRPI0809926B8 (pt) composição que compreende antígenos de mycobacterium tuberculosis, polipeptídeo de fusão isolado, polinucleotídeo isolado que codifica o dito polipeptídeo e uso da dita composição para estimular uma resposta imune protetora
BR112022014808A2 (pt) Composições e métodos para vacinas para prevenir e tratar infecção pelo coronavírus-sars-cov-2
BR112018001572A2 (pt) método para induzir uma resposta imune, antígeno, adenovírus, uso de um antígeno e de um adenovírus, e, polinucleotídeo.
BR112017020986A2 (pt) proteínas de ligação recombinantes e seu uso
WO2008054540A3 (en) Inducing immune responses to influenza virus using polypeptide and nucleic acid compositions
BR112018072485A2 (pt) proteínas de ligação biespecíficas e usos das mesmas
BRPI0721003B8 (pt) composições e uso
BR112017001940A2 (pt) proteínas de fusão de interleucina-2/receptor alfa de interleucina-2 e processos de uso
MX2019006349A (es) Proteinas recombinantes rsv f de prefusion nuevas y usos de las mismas.
BR112015021414A2 (pt) vírus da doença newcastle e seus usos
BR112022005687A2 (pt) Vacinas contra o hbv e métodos para tratar o hbv
BRPI0708519B8 (pt) vesícula semelhante ao virossoma, composição farmacêutica, uso de pelo menos uma vesícula semelhante ao virossoma, e, kit para induzir uma resposta imune contra uma proteína gp41 de um vírus da imunodeficiência humana
BRPI0815578B8 (pt) Peptídeo de cdca1, seu uso e composição imunogênica compreendendo o mesmo para induzir imunidade, tratar e/ou prevenir o câncer, bem como método in vitro para induzir uma célula apresentadora de antígeno e uma célula t citotóxica (killer)
BR112015032875A2 (pt) derivados de peptídeos do tipo glp-1, e usos dos mesmos
EP4272750A3 (en) Protein antigens that provide protection against pneumococcal colonization and/or disease
HRP20171694T1 (hr) Novi pripravci i postupci
NZ593926A (en) Methods and compositions based on shiga toxin type 2 protein
BRPI0412799A (pt) imunógeno, composição, ácido nucleico, célula recombinante, métodos para preparar um polipeptìdeo, para induzir um a resposta imune protetora em um paciente e para induzir uma resposta anamnésica em um paciente, e, seqüência de ácido nucleico otimizada de levedura
MX2022008830A (es) Mutante de fimh, composiciones que lo contienen y uso de éste.
BR112022020438A2 (pt) Composições compreendendo três proteínas de fusão ospa para uso médico
BR112016011930A2 (pt) combinações de peptídeos e seus usos em tratamento de alergia de ácaro de poeira
BR112022005159A2 (pt) Proteína de fusão fc, composição farmacêutica, método de prevenção ou tratamento de um câncer e método para induzir imunidade ou restaurar a capacidade de resposta à imunoterapia
BRPI0519923A8 (pt) polipeptídeo, seqüência de dna, vetor de dna, anticorpo, bactéria, método para produzir lps parcialmente 3-0-desacilado, composição, usos da bactéria, e de lps de bordetella isolado compreendendo lps pelo menos parcialmente 3-0-desacilado, vacina, e, método in vitro para a desacilação de lps gram-negativo ou de composições compreendendo lps gram-negativo, e, para induzir uma resposta imune contra bordetella.
BR112021024997A2 (pt) Anticorpos, polinucleotídeo, vetor de expressão, célula hospedeira, composição farmacêutica, métodos e uso
BRPI0512413A (pt) derivados de polissacarìdeo e usos na indução de uma resposta imune

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06T Formal requirements before examination [chapter 6.20 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 29/09/2020, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 04/04/2008 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B25F Entry of change of name and/or headquarter and transfer of application, patent and certif. of addition of invention: change of name on requirement

Owner name: INFECTIOUS DISEASE RESEARCH INSTITUTE (US)

Free format text: A FIM DE ATENDER A ALTERACAO DE NOME REQUERIDA ATRAVES DA PETICAO 870230044794 DE28/05/2023, E NECESSARIO MAIS UMA GRU 248 PARA ALTERACAO DE SEDE SOLICITADA NA PETICAO.

B25D Requested change of name of applicant approved

Owner name: ACCESS TO ADVANCED HEALTH INSTITUTE (US)

B25G Requested change of headquarter approved

Owner name: ACCESS TO ADVANCED HEALTH INSTITUTE (US)